M W Kieran

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi The VEGF pathway in cancer and disease: responses, resistance, and the path forward
    Mark W Kieran
    Department of Pediatric Medical Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cold Spring Harb Perspect Med 2:a006593. 2012
  2. ncbi Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors
    Mark W Kieran
    Director, Pediatric Medical Neuro Oncology, Dana Farber Cancer Institute and Boston Children s Hospital, Pediatric Hematology Oncology, Boston, MA 02215, USA
    Pediatr Blood Cancer 59:1155-7. 2012
  3. ncbi Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma
    Idoia Garcia
    Developmental Tumor Biology Laboratory, Hospital Sant Joan de Deu, Fundación Sant Joan de Déu, Barcelona, Spain
    Mol Cancer 9:277. 2010
  4. ncbi Advances in pediatric neuro-oncology
    M W Kieran
    Pediatric Medical Neuro Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Curr Opin Neurol 13:627-34. 2000
  5. ncbi Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Cons
    Mark W Kieran
    Dana Farber Cancer Institute and Children s Hospital Boston, Boston, MA 02115, USA
    J Clin Oncol 25:3137-43. 2007
  6. ncbi Anti-angiogenic therapy in pediatric neuro-oncology
    Mark W Kieran
    Harvard Medical School, USA
    J Neurooncol 75:327-34. 2005
  7. ncbi Brain tumors: from childhood through adolescence into adulthood
    Mark W Kieran
    Pediatric Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 28:4783-9. 2010
  8. ncbi A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer
    Mark W Kieran
    Department of Pediatric Oncology, Dana Farber Cancer Institute, and Division of Pediatric Hematology Oncology, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Pediatr Hematol Oncol 27:573-81. 2005
  9. ncbi New approaches to progeria
    Mark W Kieran
    Dana Farber Cancer Institute, Department of Pediatric Oncology, 44 Binney St, Boston, MA 02115, USA
    Pediatrics 120:834-41. 2007
  10. ncbi Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors
    Mark W Kieran
    Pediatric Neuro Oncology Program, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Pediatr Blood Cancer 52:169-76. 2009

Research Grants

  1. HARVARD PEDIATRIC BRAIN TUMOR CENTER
    Mark Kieran; Fiscal Year: 2003
  2. Xenogen's IVIS 100 Imaging System
    Mark Kieran; Fiscal Year: 2004

Detail Information

Publications57

  1. ncbi The VEGF pathway in cancer and disease: responses, resistance, and the path forward
    Mark W Kieran
    Department of Pediatric Medical Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cold Spring Harb Perspect Med 2:a006593. 2012
    ....
  2. ncbi Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors
    Mark W Kieran
    Director, Pediatric Medical Neuro Oncology, Dana Farber Cancer Institute and Boston Children s Hospital, Pediatric Hematology Oncology, Boston, MA 02215, USA
    Pediatr Blood Cancer 59:1155-7. 2012
    ..Targeted therapy in this disease would benefit from advanced technologies detecting relevant actionable mutations...
  3. ncbi Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma
    Idoia Garcia
    Developmental Tumor Biology Laboratory, Hospital Sant Joan de Deu, Fundación Sant Joan de Déu, Barcelona, Spain
    Mol Cancer 9:277. 2010
    ..CHD5 gene and protein expression was reexamined after induction chemotherapy in a subset of high risk tumors to identify potential changes reflecting tumor response...
  4. ncbi Advances in pediatric neuro-oncology
    M W Kieran
    Pediatric Medical Neuro Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Curr Opin Neurol 13:627-34. 2000
    ..Although many of the publications cited provide confirmation of previously reported work, when taken together they form a good framework of the state of the field from the past few years...
  5. ncbi Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Cons
    Mark W Kieran
    Dana Farber Cancer Institute and Children s Hospital Boston, Boston, MA 02115, USA
    J Clin Oncol 25:3137-43. 2007
    ..Primary objectives were to estimate the maximum-tolerated dose (MTD) and to describe the dose-limiting toxicities (DLTs) and pharmacokinetics of lonafarnib. Farnesylation inhibition of HDJ-2 in peripheral blood was also measured...
  6. ncbi Anti-angiogenic therapy in pediatric neuro-oncology
    Mark W Kieran
    Harvard Medical School, USA
    J Neurooncol 75:327-34. 2005
    ....
  7. ncbi Brain tumors: from childhood through adolescence into adulthood
    Mark W Kieran
    Pediatric Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 28:4783-9. 2010
    ..This article will discuss the changing brain tumor profile of children, adolescents, and adults, with a focus on our limited understanding of the adolescent/young adult transition period...
  8. ncbi A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer
    Mark W Kieran
    Department of Pediatric Oncology, Dana Farber Cancer Institute, and Division of Pediatric Hematology Oncology, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Pediatr Hematol Oncol 27:573-81. 2005
    ....
  9. ncbi New approaches to progeria
    Mark W Kieran
    Dana Farber Cancer Institute, Department of Pediatric Oncology, 44 Binney St, Boston, MA 02115, USA
    Pediatrics 120:834-41. 2007
    ....
  10. ncbi Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors
    Mark W Kieran
    Pediatric Neuro Oncology Program, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Pediatr Blood Cancer 52:169-76. 2009
    ..11 +/- 0.41 hr, respectively. The plasma pharmacokinetics of SU5416 in children was similar to previously reported findings in adult cancer patients. Prolonged disease stabilization was observed in 4 of 16 stratum I patients...
  11. ncbi Small molecule inhibitors in children with malignant gliomas
    Betty Herrington
    Department of Pediatric Oncology, Dana Farber Cancer Institute and Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 53:312-7. 2009
    ..This article will review small molecule inhibition of cellular pathways involved in gliomagenesis, challenges to small molecule therapy, and future directions in the use of this therapy...
  12. ncbi Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor
    Mary Ann Zimmerman
    Department of Pediatric Oncology, Pediatric Neuro-Oncology, Dana-Farber Cancer Institute, Rm # SW331, 44 Binny Street, Boston, MA 02115, USA
    J Neurooncol 72:77-84. 2005
    ..More importantly, we report on the first two survivors after relapse with multi-agent intravenous and intrathecal chemotherapy treated with this modified regimen...
  13. ncbi PPARalpha deficiency in inflammatory cells suppresses tumor growth
    Arja Kaipainen
    Vascular Biology Program, Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 2:e260. 2007
    ..These findings suggest that the absence of PPARalpha activity renders inflammatory infiltrates tumor suppressive and, thus, may provide a target for inhibiting tumor growth by modulating stromal processes, such as angiogenesis...
  14. ncbi Platelets actively sequester angiogenesis regulators
    Giannoula Lakka Klement
    Children s Hospital, Boston, MA 02115, USA
    Blood 113:2835-42. 2009
    ....
  15. ncbi Brainstem lesions in neurofibromatosis type 1
    Nicole J Ullrich
    Department of Neurology, Children s Hospital Boston, Boston, Massachusetts 02446, USA
    Neurosurgery 61:762-6; discussion 766-7. 2007
    ..The objective of this study was to define the clinical and radiographic course of brainstem lesions in children with NF1...
  16. ncbi PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
    Dipak Panigrahy
    Vascular Biology Program, Children s Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:985-90. 2008
    ..Our results provide a mechanistic rationale for evaluating the clinical benefits of PPARalpha agonists in cancer treatment, alone and in combination with other therapies...
  17. ncbi Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells
    Claire Marie Elisabeth Sauvageot
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115
    Neuro Oncol 11:109-21. 2009
    ..Our results suggest that HSP90 inhibitors like 17-AAG may have therapeutic potential in GBM, either as a single agent or in combination with radiation...
  18. ncbi Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor
    Susan N Chi
    Dana Farber Cancer Institute, Children s Hospital Boston, Boston, MA, USA
    J Clin Oncol 27:385-9. 2009
    ..Based on a previous pilot series, a prospective multi-institutional trial was conducted for patients with newly diagnosed CNS ATRT...
  19. ncbi Medical, psychological, cognitive and educational late-effects in pediatric low-grade glioma survivors treated with surgery only
    Christopher D Turner
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 53:417-23. 2009
    ..The goal of this study was to describe the multidimensional late-effects of pediatric LGG survivors treated exclusively with surgery...
  20. ncbi Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives
    David P Samuel
    Harvard Medical School, Pediatric Medical Neuro Oncology, Dana Farber Cancer Institute and Children s Hospital of Boston, Boston, MA 02115, USA
    Expert Opin Investig Drugs 18:973-83. 2009
    ....
  21. ncbi Association of rapidly progressive moyamoya syndrome with bevacizumab treatment for glioblastoma in a child with neurofibromatosis type 1
    Nicole J Ullrich
    Department of Neurology, Children s Hospital Boston, Boston, MA 02446, USA
    J Child Neurol 26:228-30. 2011
    ..We report a case of a young boy with neurofibromatosis type 1 with glioblastoma who developed rapidly progressive moyamoya vasculopathy after treatment with the angiogenesis inhibitor bevacizumab...
  22. ncbi DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium
    Sanjay P Prabhu
    Department of Radiology, Harvard Medical School, Children s Hospital Boston, 300 Longwood Ave, Boston, MA 02115, USA
    Childs Nerv Syst 27:11-8. 2011
    ....
  23. ncbi Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme
    Christopher D Turner
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Neurooncol 82:95-101. 2007
    ..In this small patient sample adding thalidomide to radiation did not improve TTP or TTD from historical controls, however, toxicity appeared to be increased...
  24. ncbi Transverse myelitis after therapy for primitive neuroectodermal tumors
    Nicole J Ullrich
    Department of Neurology, Children s Hospital Boston and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Pediatr Neurol 35:122-5. 2006
    ....
  25. ncbi Quantification of water diffusion and relaxation times of human U87 tumors in a mouse model
    Yanping Sun
    Department of Radiology, Brigham and Women s Hospital, Boston, MA 02115, USA
    NMR Biomed 17:399-404. 2004
    ..64 +/- 0.06 s. The mean T(2) in tumor was 0.062 +/- 0.002 s and in normal brain tissue was 0.048 +/- 0.001 s. The mean ADC, T1 and T2 of the tumor compared to normal tissue were significantly different (p < 0.005)...
  26. ncbi Perfusion MRI of U87 brain tumors in a mouse model
    Yanping Sun
    Department of Radiology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Magn Reson Med 51:893-9. 2004
    ..The large difference in ICBF between the tumor core and normal tissue suggests that this index might be useful for the assessment of the efficacy of antiangiogenic therapy...
  27. ncbi Psychological adjustment of 'surgery-only' pediatric neuro-oncology patients: a retrospective analysis
    Eugene A Meyer
    Dana Farber Cancer Institute, Harvard Medical School, USA
    Psychooncology 11:74-9. 2002
    ....
  28. ncbi Everyday cognitive function after craniopharyngioma in childhood
    Deborah P Waber
    Division of Psychology, Department of Psychiatry, Children s Hospital Boston, MA 02115, USA
    Pediatr Neurol 34:13-9. 2006
    ..The extent of self-rated cognitive problems is related to spatial working memory and somatic concerns...
  29. ncbi Antiangiogenesis therapy. Current and future agents
    M W Kieran
    Dana Farber Cancer Institute, Harvard Medical School Boston, Massachusetts, USA
    Hematol Oncol Clin North Am 15:835-51, viii. 2001
    ..This article reviews the current understanding of angiogenesis and its role in cancer then discusses new therapeutic options in animals and humans, with a focus on pediatric tumors and the potential for treating them...
  30. ncbi Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1
    Anita J Huttner
    Department of Pathology, Children s Hospital Boston, Boston, Massachusetts 02446, USA
    Pediatr Blood Cancer 54:890-6. 2010
    ..There is also an increased risk of developing malignant tumors. Glioblastoma is an uncommon, malignant tumor of children that is even less frequently observed in children with NF1...
  31. ncbi A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors
    Joshua B Rubin
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:13513-8. 2003
    ....
  32. ncbi Therapeutic potential of thiazolidinediones as anticancer agents
    Dipak Panigrahy
    Children's Hospital, Research Building, Floor 12, Boston, MA, USA
    Expert Opin Investig Drugs 12:1925-37. 2003
    ..Further studies suggest that TZDs may be effective in prevention of certain cancers and in the treatment of cancer as adjuvant therapy...
  33. ncbi Psychosocial and behavioral functioning among pediatric brain tumor survivors
    Sarah C Carpentieri
    Division of Psychology, Children s Hospital, Boston, MA, USA
    J Neurooncol 63:279-87. 2003
    ..To describe the psychosocial and behavioral functioning, as described by patient, parent and teacher, of a cohort of adolescents who have been previously treated for a brain tumor...
  34. ncbi Neuropsychological functioning after surgery in children treated for brain tumor
    Sarah C Carpentieri
    Division of Psychology, Department of Psychiatry, Children s Hospital, Boston, MA, USA
    Neurosurgery 52:1348-56; discussion 1356-7. 2003
    ..Subsequent reports will describe the neuropsychological functioning of children treated with surgery and stereotactic radiation therapy on Dana-Farber Cancer Institute 92-077...
  35. ncbi Chemotherapy for progressive low-grade gliomas in children older than ten years: the Dana-Farber experience
    John A Heath
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Pediatr Hematol Oncol 20:497-504. 2003
    ..A prospective clinical trial of chemotherapy for progressive low-grade gliomas in children older than 10 years is therefore warranted...
  36. ncbi Memory deficits among children with craniopharyngiomas
    S C Carpentieri
    Division of Psychology, Department of Psychiatry, Children s Hospital and Harvard Medical School, 300 Longwood Ave, Boston, Massachusetts 02115, USA
    Neurosurgery 49:1053-7; discussion 1057-8. 2001
    ..To describe neuropsychological functioning (with a specific focus on cognition and memory) after surgical treatment of craniopharyngiomas...
  37. ncbi Anti-angiogenic chemotherapy in central nervous system tumors
    Mark W Kieran
    Harvard Medical School, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Treat Res 117:337-49. 2004
    ..A number of excellent reviews covering related aspects of this topic are also available (1-13)...
  38. ncbi Basement membrane derived fibulin-1 and fibulin-5 function as angiogenesis inhibitors and suppress tumor growth
    Liang Xie
    Division of Matrix Biology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Exp Biol Med (Maywood) 233:155-62. 2008
    ..Additionally, degradation of basement membrane by cathepsin D liberates both fibulin-1 fragments and fibulin-5, which function to inhibit angiogenesis...
  39. ncbi Anti-apoptosis mechanisms in malignant gliomas
    David S Ziegler
    Department of Pediatric Oncology, Dana Farber Cancer Institute and Children s Hospital, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 26:493-500. 2008
    ....
  40. ncbi PPARgamma as a therapeutic target for tumor angiogenesis and metastasis
    Dipak Panigrahy
    Vascular Biology Program, Children's Hospital, Department of Surgery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Biol Ther 4:687-93. 2005
    ..This will be paramount if the potent biological activity of PPARgamma agonists are to be harnessed for cancer therapy...
  41. ncbi Moyamoya following cranial irradiation for primary brain tumors in children
    N J Ullrich
    Department of Neurology, Children s Hospital Boston, Boston, MA 02446, USA
    Neurology 68:932-8. 2007
    ..To study the risk factors for the development of moyamoya syndrome after cranial irradiation for primary brain tumors in children...
  42. ncbi Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation
    Margaret E McLaughlin
    Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
    J Pediatr Hematol Oncol 25:644-8. 2003
    ....
  43. ncbi A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors
    Peter Manley
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Children s Hospital, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 53:343-7. 2009
    ..Brain tumors have been reported to express high plasma levels of A-PROTEIN, suggesting that it may be of significant diagnostic and prognostic value...
  44. ncbi Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas
    Matija Snuderl
    Pathology Service, Massachusetts General Hospital, Boston, MA 02114, USA
    J Neuropathol Exp Neurol 67:911-20. 2008
    ....
  45. ncbi Profiling critical cancer gene mutations in clinical tumor samples
    Laura E MacConaill
    Center for Cancer Genome Discovery, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 4:e7887. 2009
    ..We report the implementation of a genotyping and validation algorithm that enables robust tumor mutation profiling in the clinical setting...
  46. ncbi Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy
    Stephen W Gilheeney
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Neurooncol 89:89-95. 2008
    ....
  47. ncbi Cutaneovisceral angiomatosis with thrombocytopenia
    Vinay Prasad
    Department of Pathology, Children's Hospital, Harvard Medical School, Boston, MA 02115, USA
    Pediatr Dev Pathol 8:407-19. 2005
    ..We have termed this relatively indolent or slowly progressive disorder cutaneovisceral angiomatosis with thrombocytopenia because this designation incorporates its major clinical and histopathologic features...
  48. ncbi Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report
    Ian F Pollack
    Department of Neurosurgery, Children s Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA
    Neuro Oncol 9:145-60. 2007
    ..Imatinib may increase the risk of ITH, although the incidence of spontaneous hemorrhages in brainstem glioma is sufficiently high that this should be considered in studies of agents in which hemorrhage is a concern...
  49. ncbi Treatment of low-grade gliomas in children: an update
    Stergios Zacharoulis
    Pediatric Oncology Neural Tumor, Children s Hospital Los Angeles, 4650 Sunset Boulevard, 99, Los Angeles, CA 90027, USA
    Expert Rev Neurother 4:1005-14. 2004
    ..Balancing surgery, radiation and chemotherapy to optimize disease control while limiting treatment-related morbidity is of critical importance in this susceptible population and is the focus of this review...
  50. ncbi AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma
    Sith Sathornsumetee
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 66:8722-30. 2006
    ....
  51. ncbi ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors
    Jeremy N Rich
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:8145-57. 2005
    ..Current nonspecific therapies frequently have poor efficacy in many of these tumor types, so there is a pressing need for the development of novel targeted therapies...
  52. ncbi Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012
    Tobey J Macdonald
    Children s National Medical Center, 111 Michigan Ave, NW, Washington, DC 20010, USA
    J Clin Oncol 26:919-24. 2008
    ....
  53. ncbi The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study
    Harry Applebaum
    Division of Pediatric Surgery, Kaiser Permanente Medical Center, Los Angeles, CA 90027, USA
    J Pediatr Surg 40:999-1003; discussion 1003. 2005
    ....
  54. ncbi Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development
    Leslie B Gordon
    Department of Pediatrics, Rhode Island Hospital, Providence, Rhode Island, USA
    Pediatrics 120:824-33. 2007
    ..We sought to more clearly define the bone and weight abnormalities in patients with progeria as potential outcome parameters for prospective clinical trials...
  55. ncbi Remission of infantile generalized myofibromatosis after interferon alpha therapy
    Cinzia Auriti
    Department of Neonatology, Bambino Gesu Children s Hospital, Rome, Italy
    J Pediatr Hematol Oncol 30:179-81. 2008
    ..The tumors regressed and vascular endothelial growth factor and fibroblast growth factor-2 levels were reduced after treatment discontinuation...
  56. ncbi Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: Proceedings from the 1st International Costello Syndrome Research Symposium 2007
    Katherine A Rauen
    Department of Pediatrics, Division of Medical Genetics, University of California, San Francisco, California, USA
    Am J Med Genet A 146:1205-17. 2008
  57. ncbi Angiogenesis inhibitors and hypoxia
    Mark W Kieran
    Nat Med 9:1104; author reply 1104-5. 2003

Research Grants2

  1. HARVARD PEDIATRIC BRAIN TUMOR CENTER
    Mark Kieran; Fiscal Year: 2003
    ..David Louis). In summary, we will bring the full thrust of a Comprehensive Cancer Center and the full services of a pediatric center to enhance the Consortium and our mutual missions. ..
  2. Xenogen's IVIS 100 Imaging System
    Mark Kieran; Fiscal Year: 2004
    ..This luciferase-based technology affords a superior method to achieve this aim. ..